bluebird bio (NASDAQ:BLUE) Stock Rating Upgraded by JPMorgan Chase & Co.

JPMorgan Chase & Co. upgraded shares of bluebird bio (NASDAQ:BLUE) from an underweight rating to a neutral rating in a research note issued to investors on Monday morning, MarketBeat.com reports.

Other equities research analysts have also recently issued reports about the company. Royal Bank of Canada reiterated a “sector perform” rating and set a $80.00 target price on shares of bluebird bio in a research note on Friday, November 15th. Bank of America lowered shares of bluebird bio from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $60.00 to $10.00 in a research report on Friday, November 15th. Barclays increased their target price on shares of bluebird bio from $2.00 to $40.00 and gave the company an “overweight” rating in a research report on Tuesday, December 31st. Finally, StockNews.com began coverage on shares of bluebird bio in a report on Friday, December 20th. They issued a “sell” rating on the stock. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $44.14.

bluebird bio Stock Performance

Shares of bluebird bio stock opened at $3.86 on Monday. The business’s fifty day simple moving average is $7.63 and its 200 day simple moving average is $9.25. The company has a current ratio of 0.51, a quick ratio of 0.33 and a debt-to-equity ratio of 0.37. bluebird bio has a 12 month low of $3.56 and a 12 month high of $38.40. The firm has a market capitalization of $37.53 million, a P/E ratio of -0.10 and a beta of 0.68.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Regeneron Pharmaceuticals Inc. bought a new position in shares of bluebird bio in the fourth quarter worth $175,000. Verition Fund Management LLC purchased a new stake in bluebird bio during the 3rd quarter worth about $42,000. SG Americas Securities LLC boosted its stake in bluebird bio by 152.4% in the 3rd quarter. SG Americas Securities LLC now owns 122,855 shares of the biotechnology company’s stock worth $64,000 after purchasing an additional 74,185 shares during the period. Captrust Financial Advisors grew its holdings in bluebird bio by 48.2% during the 3rd quarter. Captrust Financial Advisors now owns 237,648 shares of the biotechnology company’s stock valued at $123,000 after buying an additional 77,293 shares in the last quarter. Finally, Barclays PLC increased its position in shares of bluebird bio by 273.7% during the third quarter. Barclays PLC now owns 252,062 shares of the biotechnology company’s stock valued at $130,000 after buying an additional 184,605 shares during the period. 87.43% of the stock is currently owned by hedge funds and other institutional investors.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.